Spero Therapeutics (SPRO) Shares Outstanding (Weighted Average) (2016 - 2026)

Spero Therapeutics has reported Shares Outstanding (Weighted Average) for 11 years, with the latest figure at $57.3 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.44% year-over-year to $57.3 million; the trailing twelve-month figure through Mar 2026 stood at $57.3 million (up 3.44% YoY), and the FY2025 full-year result was $56.0 million, up 3.67% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $57.3 million, up from $56.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $57.3 million in Q1 2026, with the low at $32.6 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $49.7 million across 5 years, with a median of $53.5 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) jumped 61.09% — and 2024, when it climbed 1.9%.
• Spero Therapeutics' Shares Outstanding (Weighted Average) stood at $37.6 million in 2022, then surged by 40.22% to $52.7 million in 2023, then climbed by 2.53% to $54.0 million in 2024, then climbed by 3.67% to $56.0 million in 2025, then grew by 2.25% to $57.3 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $57.3 million (Q1 2026), $56.0 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.